Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker OPK · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Aug 27, 2026 | Phase 1/2 Study of OPK-88006 in Healthy and Presumed MASH Participants NCT07512427 · MASH OPK-88006, Placebo | OPK OPKO Health, Inc. | Phase 1/2 | Recruiting | 30 | Dec 2027 | Registry ↗ |
| Aug 20, 2026 | Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release… NCT07494045 · CKD Stage 3, CKD Stage 4 CTAP101 | OPK OPKO Health, Inc. | Phase 2 | Recruiting | 40 | Oct 2027 | Registry ↗ |
| Apr 3, 2026 | Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI NCT03602261 · Secondary Hyperparathyroidism Due to Renal Causes, Chronic… Calcifediol Oral Capsule, Placebo oral capsule | OPK OPKO Health, Inc. | Phase 2 | Terminated | 44 | Feb 24, 2021 | Registry ↗ |
| Jul 25, 2025 | Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary H… NCT05543928 · Chronic Kidney Disease stage3, Chronic Kidney Disease stage4 CTAP101, Placebo | OPK OPKO Health, Inc. | Phase 3 | Terminated | 2 | Jun 19, 2024 | Registry ↗ |
| Jul 20, 2025 | Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children NCT02968004 · Pediatric Growth Hormone Deficiency MOD-4023, Somatropin | OPK OPKO Health, Inc. | Phase 3 | Completed | 224 | Aug 2019 | Registry ↗ |
| Apr 9, 2025 | Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children NCT02500316 · Growth Hormone Deficiency (GHD) MOD-4023 | OPK OPKO Health, Inc. | Phase 2 | Completed | 48 | Nov 2023 | Registry ↗ |
| May 28, 2024 | Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19 NCT04551911 · COVID-19, Coronavirus Rayaldee, Placebo | OPK OPKO Health, Inc. | Phase 2 | Completed | 171 | Oct 8, 2021 | Registry ↗ |
| Dec 9, 2022 | Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release C… NCT03588884 · Secondary Hyperparathyroidism Due to Renal Causes, Vitamin… Calcifediol Oral Capsule, Calcifediol Oral Product | OPK OPKO Health, Inc. | Phase 4 | Completed | 69 | Apr 24, 2020 | Registry ↗ |
| Aug 12, 2022 | A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth… NCT01909479 · Adult Growth Hormone Deficiency MOD-4023, Placebo | OPK OPKO Health, Inc. | Phase 3 | Terminated | 202 | Aug 2016 | Registry ↗ |
| Sep 16, 2021 | Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasi… NCT03297398 · Benign Prostatic Hyperplasia Group-1 (15mg, OPK-88004), Group-2 (25 mg,OPK-88004) | OPK OPKO Health, Inc. | Phase 2 | Terminated | 114 | Apr 18, 2019 | Registry ↗ |
| Aug 12, 2021 | Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency NCT03874013 · Growth Hormone Deficiency MOD-4023, Genotropin | OPK OPKO Health, Inc. | Phase 3 | Completed | 44 | Mar 6, 2020 | Registry ↗ |
| Jun 15, 2021 | Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects NCT03406377 · Type 2 Diabetes Mellitus OPK-88003, Placebo | OPK OPKO Health, Inc. | Phase 2 | Completed | 113 | Mar 8, 2019 | Registry ↗ |
| May 27, 2021 | A Study of LY2944876 in Healthy Japanese and Non-Japanese Participants NCT02188303 · Healthy Volunteers LY2944876, Placebo | OPK OPKO Health, Inc. | Phase 1 | Terminated | 48 | Dec 2014 | Registry ↗ |
| May 27, 2021 | A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available f… NCT02119819 · Diabetes Mellitus, Type 2 LY2944876, Exenatide extended-release | OPK OPKO Health, Inc. | Phase 2 | Completed | 420 | Aug 2015 | Registry ↗ |
| May 20, 2021 | A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B NCT02418793 · Hemophilia A, Hemophilia B MOD-5014 | OPK OPKO Health, Inc. | Phase 1 | Completed | 27 | Sep 2018 | Registry ↗ |
| Mar 23, 2021 | Quality of Life and Visual Acuity of Visglyc Eye Drops on Dry Eye Patients NCT04063644 · Dry Eye Syndromes, Cataract Vis Glyc Neo, Physiological saline solution | OPK OPKO Health, Inc. | Not applicable | Completed | 100 | Dec 22, 2020 | Registry ↗ |
| Mar 23, 2021 | Efficacy and Safety of a Intra-articular Injection, ENKO1, in Patients With Symptomatic Knee Osteoa… NCT03762408 · Osteoarthritis, Knee ENKO 1, Durolane | OPK OPKO Health, Inc. | Not applicable | Completed | 175 | May 29, 2020 | Registry ↗ |
| Apr 28, 2020 | A Clinical Study Investigating the Comparability of Somatrogon in Two Different Drug Product Presen… NCT03810664 · Healthy Male Volunteers Somatrogon | OPK OPKO Health, Inc. | Phase 1 | Completed | 49 | Apr 19, 2019 | Registry ↗ |
| Jan 23, 2020 | Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children NCT01592500 · Pediatric Growth Hormone Deficiency MOD-4023, Somatropin | OPK OPKO Health, Inc. | Phase 2 | Completed | 56 | Jul 2015 | Registry ↗ |
| Nov 4, 2019 | A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia NCT01791725 · Down Syndrome ELND005, Placebo | OPK OPKO Health, Inc. | Phase 2 | Completed | 23 | Jun 2014 | Registry ↗ |
| Nov 1, 2019 | ELND005 in Patients With Mild to Moderate Alzheimer's Disease NCT00568776 · Alzheimer Disease Placebo Control, ELND005 | OPK OPKO Health, Inc. | Phase 2 | Completed | 353 | May 2010 | Registry ↗ |
| Oct 21, 2019 | A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheime… NCT01766336 · Alzheimer's Disease Group 1 ELND005, Group 2 ELND005 | OPK OPKO Health, Inc. | Phase 2 | Terminated | 296 | Aug 2015 | Registry ↗ |
| Oct 21, 2019 | Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Dis… NCT01735630 · Alzheimer's Disease ELND005, Placebo | OPK OPKO Health, Inc. | Phase 2 | Completed | 350 | May 2015 | Registry ↗ |
| Oct 21, 2019 | Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder NCT01674010 · Bipolar 1 Disorder ELND005, Lamotrigine | OPK OPKO Health, Inc. | Phase 2 | Terminated | 309 | Jun 2014 | Registry ↗ |
| Oct 21, 2019 | ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease NCT00934050 · Alzheimer's Disease ELND005 (scyllo-inositol) | OPK OPKO Health, Inc. | Phase 2 | Completed | 103 | Jun 2011 | Registry ↗ |
| Oct 18, 2019 | A Study in Type 2 Diabetic Patients With Repeated Doses of E1 in Combination With G1 NCT00239187 · Type 2 Diabetes E1 and G1 | OPK OPKO Health, Inc. | Phase 1 | Completed | 30 | — | Registry ↗ |
| Oct 18, 2019 | A Study in Type 1 Diabetic Patients With Repeated Doses of E1 in Combination With G1 NCT00239148 · Type 1 Diabetes E1 and G1 | OPK OPKO Health, Inc. | Phase 1 | Completed | 20 | — | Registry ↗ |
| Oct 18, 2019 | Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and Ribavi… NCT00230854 · Chronic Hepatitis C, Hepatitis, Viral, Human EMZ702 | OPK OPKO Health, Inc. | Phase 1 | Completed | 28 | — | Registry ↗ |
| Oct 17, 2019 | 4Kscore Using Serum Stored Uncentrifuged NCT04130776 · Prostate Cancer Measurement of four prostate-specific kallikreins for the 4… | OPK OPKO Health, Inc. | — | Completed | 64 | Mar 27, 2018 | Registry ↗ |
| Oct 8, 2019 | MOD-4023 (Long-Lasting Human Growth Hormone (hGH)) Study in Growth Hormone Deficient Adults (GHDA) NCT01225666 · Adult Growth Hormone Deficiency MOD-4023, MOD-4023 | OPK OPKO Health, Inc. | Phase 2 | Completed | 52 | Jul 2011 | Registry ↗ |
| Sep 30, 2019 | Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects… NCT03660800 · Vitamin D Insufficiency, Secondary Hyperparathyroidism CTAP101 Capsules | OPK OPKO Health, Inc. | Phase 1 | Completed | 67 | Oct 24, 2018 | Registry ↗ |
| Sep 30, 2019 | A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult Male NCT02919800 · Hemophilia A or B With Inhibitors MOD-5014, MOD-5014 Placebo | OPK OPKO Health, Inc. | Phase 1 | Completed | 32 | Feb 21, 2018 | Registry ↗ |
| Sep 30, 2019 | A Single-dose, Dose-escalation Study of a Long-acting MOD-6031 in Healthy Overweight or Obese Subje… NCT02692781 · Obesity MOD-6031, Placebo control | OPK OPKO Health, Inc. | Phase 1 | Completed | 32 | Dec 15, 2016 | Registry ↗ |
| Sep 30, 2019 | Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023)… NCT02418767 · Growth Hormone Deficiency MOD-4023, Placebo | OPK OPKO Health, Inc. | Phase 1 | Completed | 42 | Mar 2015 | Registry ↗ |
| Sep 30, 2019 | MOD-4023 Study in Healthy Male Volunteers NCT01060722 · Healthy MOD-4023 (long lasting hGH), Placebo | OPK OPKO Health, Inc. | Phase 1 | Completed | 24 | Jan 2010 | Registry ↗ |
| Sep 27, 2019 | Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Deno… NCT02274623 · Breast Cancer, Prostate Cancer CTAP101 Capsules | OPK OPKO Health, Inc. | Phase 1 | Completed | 33 | Feb 27, 2017 | Registry ↗ |
| Nov 30, 2017 | Efficacy and Tolerability of a Nutritional Supplement, Plactive Progen, in ACL Reconstruction NCT03355651 · ACL Reconstruction PROGEN | OPK OPKO Health, Inc. | Not applicable | Completed | 80 | Feb 1, 2017 | Registry ↗ |
| Sep 29, 2016 | Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002 NCT02282813 · Chronic Kidney Disease, Hyperparathyroidism, Secondary CTAP101 Capsules, Calcitriol | OPK OPKO Health, Inc. | Phase 3 | Completed | 298 | May 2015 | Registry ↗ |
| Aug 25, 2016 | Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroid… NCT01219855 · Chronic Kidney Disease, Secondary Hyperparathyroidism Cohort 1 CTAP101 Capsules- 60µg, Cohort 1 CTAP101 Capsules… | OPK OPKO Health, Inc. | Phase 2/3 | Completed | 78 | Nov 2011 | Registry ↗ |
| Mar 6, 2015 | Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CA… NCT00557791 · Age Related Macular Degeneration Bevasiranib, ranibizumab | OPK OPKO Health, Inc. | Phase 3 | Withdrawn | 0 | Jul 2011 | Registry ↗ |
40 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:51 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances